Protocol Ledger

NCT07241390 · Phase III · RECRUITING

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Interventional Phase III clinical trial protocol NCT07241390 sponsored by Eli Lilly and Company in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-01 Enrollment: 7,140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07241390
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)7,140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07241390
Protocol FieldVerified Registry Value
NCT IdentifierNCT07241390
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment7,140 participants (ESTIMATED)
Registered Start Date2025-12-01
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI